Literature DB >> 24577514

Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.

Sylvia T Singer1, Frans Kuypers, Jeffery Fineman, Ginny Gildengorin, Sandra Larkin, Nancy Sweeters, Howard Rosenfeld, Gregory Kurio, Annie Higa, Michael Jeng, James Huang, Elliott P Vichinsky.   

Abstract

A high tricuspid regurgitant jet velocity (TRV) signifies a risk for or established pulmonary hypertension (PH), which is a serious complication in thalassemia patients. The underlying pathophysiology in thalassemia subgroups and potential biomarkers for early detection and monitoring are not well defined, in particular as they relate to spleen removal. To better understand some of these unresolved aspects, we examined 76 thalassemia patients (35 non-transfused), 25 splenectomized non-thalassemia patients (15 with hereditary spherocytosis), and 12 healthy controls. An elevated TRV (>2.5 m/s) was found in 25/76 (33 %) of the patients, confined to non-transfused or those with a late start of transfusions, including patients with hemoglobin H-constant spring, a finding not previously described. These non or late-transfused patients (76 % splenectomized) had significantly increased platelet activation (sCD40L), high platelet count, endothelial activation (endothelin-1), and hemolysis (LDH, plasma-free Hb), while hypercoagulable and inflammatory markers were not significantly increased. The same markers were increased in the seven patients with confirmed PH on cardiac catheterization, suggesting their possible role for screening patients at risk for PH. A combination of hemolysis and absence of spleen is necessary for developing a high TRV, as neither chronic hemolysis in the non-splenectomized thalassemia patients nor splenectomy without hemolysis, in the non-thalassemia patients, resulted in an increase in TRV.

Entities:  

Mesh:

Year:  2014        PMID: 24577514      PMCID: PMC4467727          DOI: 10.1007/s00277-014-2037-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  49 in total

1.  Pulmonary hypertension and NO in sickle cell.

Authors:  Mark T Gladwin; Robyn J Barst; Oswaldo L Castro; Victor R Gordeuk; Cheryl A Hillery; Gregory J Kato; Daniel B Kim-Shapiro; Roberto Machado; Claudia R Morris; Martin H Steinberg; Elliott P Vichinsky
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

Review 2.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Authors:  H Franklin Bunn; David G Nathan; George J Dover; Robert P Hebbel; Orah S Platt; Wendell F Rosse; Russell E Ware
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

3.  Splenectomy and thrombosis: the case of thalassemia intermedia.

Authors:  A T Taher; K M Musallam; M Karimi; A El-Beshlawy; K Belhoul; S Daar; M Saned; C Cesaretti; M D Cappellini
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

4.  Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia.

Authors:  Athanasios Aessopos; Dimitrios Farmakis; Spyros Deftereos; Maria Tsironi; Stergios Tassiopoulos; Ioannis Moyssakis; Markisia Karagiorga
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

5.  Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity.

Authors:  Frans A Kuypers; Sandra K Larkin; Jef J Emeis; Anthony C Allison
Journal:  Thromb Haemost       Date:  2007-03       Impact factor: 5.249

6.  Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets.

Authors:  D Varon; D E Jackson; B Shenkman; R Dardik; I Tamarin; N Savion; P J Newman
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

7.  Frequency of pulmonary hypertension in asymptomatic β-thalassemia major patients and the role of physiological parameters in evaluation.

Authors:  Goksel Kiter; Yasemin Isik Balci; Akin Ates; Sibel Hacioglu; Ismail Sari
Journal:  Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.969

8.  Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease.

Authors:  Pantep Angchaisuksiri; Vichai Atichartakarn; Katcharin Aryurachai; Napaporn Archararit; Suporn Chuncharunee; Arjit Tiraganjana; Sasivimol Rattanasiri
Journal:  Am J Hematol       Date:  2007-11       Impact factor: 10.047

9.  Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia.

Authors:  A Aessopos; G Stamatelos; V Skoumas; G Vassilopoulos; M Mantzourani; D Loukopoulos
Journal:  Chest       Date:  1995-01       Impact factor: 9.410

10.  Oxidative status of platelets in normal and thalassemic blood.

Authors:  Johnny Amer; Eitan Fibach
Journal:  Thromb Haemost       Date:  2004-11       Impact factor: 5.249

View more
  6 in total

1.  Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Authors:  Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers
Journal:  Br J Haematol       Date:  2015-04-24       Impact factor: 6.998

2.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

3.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

Review 4.  HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.

Authors:  Rhoda Elison Hirsch; Nathawut Sibmooh; Suthat Fucharoen; Joel M Friedman
Journal:  Antioxid Redox Signal       Date:  2016-11-28       Impact factor: 8.401

5.  The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension.

Authors:  Hossein Karami; Hadi Darvishi-Khezri; Mehrnoush Kosaryan; Rosetta Akbarzadeh; Mojdeh Dabirian
Journal:  Int Med Case Rep J       Date:  2018-12-17

6.  Post splenectomy related pulmonary hypertension.

Authors:  Atul V Palkar; Abhinav Agrawal; Sameer Verma; Asma Iftikhar; Edmund J Miller; Arunabh Talwar
Journal:  World J Respirol       Date:  2015-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.